Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Shirakata Y et al. | Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. | 1995 | Transplantation | pmid:8545894 |
Leroy-Matheron C et al. | Inhibitor against coagulation factor V after liver transplantation. | 1999 | Transplantation | pmid:10532550 |
Abbott KC et al. | New-onset gout after kidney transplantation: incidence, risk factors and implications. | 2005 | Transplantation | pmid:16340779 |
Bayer ND et al. | Association of metabolic syndrome with development of new-onset diabetes after transplantation. | 2010 | Transplantation | pmid:20724958 |
Kiuchi T et al. | A hepatic graft tuberculosis transmitted from a living-related donor. | 1997 | Transplantation | pmid:9089234 |
Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
Newell KA et al. | Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. | 1996 | Transplantation | pmid:8779685 |
Heilman RL et al. | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | 2011 | Transplantation | pmid:21775930 |
Jain A et al. | Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 | Transplantation | pmid:10653398 |
Yamazaki S et al. | Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. | 2008 | Transplantation | pmid:18852671 |
Stevens RB et al. | A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. | 2015 | Transplantation | pmid:25083614 |
Florescu DF et al. | Adenovirus infections in pediatric small bowel transplant recipients. | 2010 | Transplantation | pmid:20467354 |
Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
Opelz G and Döhler B | Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. | 2008 | Transplantation | pmid:18698238 |
Apanay DC et al. | Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. | 1994 | Transplantation | pmid:7524202 |
Raggi MC et al. | Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. | 2010 | Transplantation | pmid:21076373 |
Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
Ueki S et al. | Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | 2006 | Transplantation | pmid:17198266 |
Murase N et al. | Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. | 1993 | Transplantation | pmid:7678353 |
Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |